Amicus Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Amicus Therapeutics

01/03/2023 14:34

* Amicus Therapeutics Inc  FOLD.OQ  reported a quarterly
adjusted
loss of 19 cents​​ per share for the quarter ended in December.
The mean expectation of twelve analysts for the quarter was
for a loss of 13 cents per share.
    * Revenue rose 7.2% to $88.10 million from a year ago;
analysts
expected $86.29 million. 
    * Amicus Therapeutics Inc's reported EPS for the quarter was
a
loss of 19 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.7%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Amicus Therapeutics Inc shares had risen by 8.0% this
quarter.
    * The company reported a quarterly loss of $55.87 million.
    * Wall Street's median 12-month price target for Amicus
Therapeutics Inc is $16.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data March 1
at 02:33 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.13          -0.19          Missed
 Sep. 30 2022      -0.19          -0.12          Beat
 Jun. 30 2022      -0.22          -0.21          Beat
 Mar. 31 2022      -0.25          -0.30          Missed